Vertaling van "interest when assessing that risk " (Nederlands → Frans) :

LUCAS has studied the literature on the measuring instruments available and on the points of special interest when assessing that risk (context, objective, the health professional’s attitude and skills…).
L’interview se fera auprès de différents groupes professionnels (médecins généralistes, pharmaciens, collaborateurs des CGG, collaborateurs des lignes d’aide téléphonique…) et auprès des étudiants.

This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.
Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments.

Een bijkomend aandachtspunt, beklemtoond in het werkstuk van de Hoge Gezondheidsraad, is artsen te herinneren aan het algemeen aanvaard deontologisch principe van het voorkomen van een " conflict of interest" : " A conflict of interest that may arise when the healthcare professionals involved in the counseling are employed by or linked to the companies selling the tests" .
Un autre aspect important mis en évidence par le document du CSS est de rappeler aux médecins le principe déontologique généralement admis de la prévention d'un « conflit d'intérêts » : « A conflict of interest that may arise when the healthcare professionals involved in the couseling are employed by or linked to the companies selling the tests». [traduction libre : Un conflit d'intérêts qui peut apparaître lorsque des professionnels des soins de santé remplissent un rôle de conseil alors qu'ils sont employés par les firmes vendant les tests ou ont un lien avec celles-ci.].

►When a risk is identified, begin assessment by questioning if the risk can be eliminated.
►Lorsqu’un risque est identifié, commencer l’ER en s’interrogeant sur la possibilité d’élimination du risque.

Goodwill and acquired In-Process Research & Development (IPR&D) projects not yet ready for use are subject to impairment review at least annually, or when events have occurred that require an assessment.
Le goodwill et les projets acquis, intégrés dans le processus de recherche et développement et qui ne sont pas encore prêts à être utilisés, font l’objet d’un test de dépréciation au moins annuel ou quand des événements surgissent qui nécessitent de les évaluer.

Intervention When a MRSA colonised or infected patient leaves the hospital to receive ambulatory care, it is recommended that the general practitioner be fully informed of the follow-up of MRSA colonisation or infection through the discharge medical report and any additional standard document Patients recently hospitalised for more than 24 hours or transferred from another hospital or presenting risk factors for MRSA colonisation must be isolated.
Quand le patient colonisé ou infecté par MRSA quitte l’hôpital pour recevoir des soins ambulatoires, il est conseillé d’informer de manière complète le médecin généraliste du suivi de la colonisation ou de l’infection à MRSA au moyen du rapport médical de renvoi ou de tout document standard supplémentaire.

The roles that pharmacists could play in this issue are: the ability to recognise risk factors such as a previous attempted suicide or the abusive use of medication, referring patients to health professionals when suspecting the early stages of a depression, and also to a certain extent following-up compliance and providing information on the side effects of the medicine.
Les rôles qui pourraient être attribués aux pharmaciens dans la problématique sont: savoir reconnaître les facteurs de risque comme une tentative de suicide antérieure ou l’abus de médicaments problématique, l’orientation vers des intervenants en cas de soupçon de début de dépression, et dans une certaine mesure également, le suivi de la compliance et l’information sur les effets secondaires des médicaments.

Such risks and uncertainties include, among other things, the uncertainties inherent in research and development; whether and when regulatory authorities in countries where regulatory applications for Prevenar 13 may be pending or may be submitted will approve such applications and their decisions regarding labeling and other matters that could affect its availability or commercial potential; and competitive developments.
This release contains forward-looking information that involves substantial risks and uncertainties regarding Prevenar 13, including its potential benefits; and the success of the AMC project for vaccines. Such risks and uncertainties include, among other things, the uncertainties inherent in research and development; whether and when regulatory authorities in countries where regulatory applications for Prevenar 13 may be pending or may be submitted will approve such applications and their decisions regarding labeling and other matters that could affect its availability or commercial potential; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009, and in its reports on Form 10-Q and Form 8-K.

►Structure the assessment to ensure that all relevant hazards and risks are addressed (e.g. not overlooking secondary tasks, such as cleaning).
►L’ER doit être structurée de manière à garantir que tous les dangers et risques à prendre en considération sont abordés (p. ex. ne pas négliger des tâches secondaires comme l’entretien).